The FDA has approved a two-drug combination for advanced melanoma patients. The combo, made by Bristol-Myers Squibb, is expected to cost $250,000 for one year. Expected gain in life is measured in months, but some subsets may experience a dramatic benefit. The real question is: Who are those patients?
